Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072537594> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2072537594 endingPage "494" @default.
- W2072537594 startingPage "489" @default.
- W2072537594 abstract "The efficacy and safety of the new long-acting dopamine agonist cabergoline were evaluated in 127 hyperprolactinemic patients (124F and 3M; 71 with microprolactinoma, 14 with macroprolactinoma, 5 with operated macroprolactinoma and 37 with idiopathic disorder) who were treated with the drug for from 3 to 52 months (median, 14 months). Cabergoline was administered orally at dose levels ranging between 0.2 and 3.5mg per week, given once weekly in 92 patients, twice weekly in 22, thrice weekly in 9 and daily in 4. Serum prolactin and progesterone levels, hematology, blood chemistry and electrocardiograms were frequently evaluated throughout treatment. CT or MR imaging of the pituitary was repeated during treatment in patients with macroprolactinoma and in 38 with microprolactinoma. After drug discontinuation, serum prolactin and gonadal function were evaluated monthly for three months in 65 patients and for up to two years in 12. Serum prolactin levels were normalized in 114 patients (90%). Of 56 women with amenorrhea, 52 resumed menses (with presumptive evidence of ovulation in 49); 17 women became pregnant; and sexual potency was restored in the 3 men. Evidence of tumor shrinkage was obtained in 13 of the 14 patients with macroprolactinoma and in 28 of 38 with microprolactinoma; complete disappearance of the tumor image was achieved in 2 macro and 14 microprolactinomas. A total of 48 adverse events was reported by 29 patients (2 3%), almost all typical of the pharmacological class and mild to moderate; no patient withdrew from treatment due to adverse events. Safety parameters did not change. Following cabergoline discontinuation, prolactin levels increased slowly, being still markedly lower than pretreatment values after three months; 10 patients out of 32 had persistently normal prolactin levels during one year of follow-up. Of 28 previously amenorrheic women who resumed menses during treatment and were followed for at least six months after cabergoline withdrawal, 23 continued to have cyclic ovulatory menses. These efficacy and safety data, including those obtained on drug withdrawal, compare favorably with those reported for bromocriptine and other prolactin-lowering drugs. Because of its very simple administration schedule, which should increase patient compliance, cabergoline may become the drug of choice for hyperprolactinemic disorders." @default.
- W2072537594 created "2016-06-24" @default.
- W2072537594 creator A5014897645 @default.
- W2072537594 creator A5022692101 @default.
- W2072537594 creator A5022734219 @default.
- W2072537594 creator A5033522929 @default.
- W2072537594 creator A5069526986 @default.
- W2072537594 creator A5089683087 @default.
- W2072537594 date "1992-06-01" @default.
- W2072537594 modified "2023-10-18" @default.
- W2072537594 title "Cabergoline in the long-term therapy of hyperprolactinemic disorders" @default.
- W2072537594 doi "https://doi.org/10.1530/acta.0.1260489" @default.
- W2072537594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1642081" @default.
- W2072537594 hasPublicationYear "1992" @default.
- W2072537594 type Work @default.
- W2072537594 sameAs 2072537594 @default.
- W2072537594 citedByCount "104" @default.
- W2072537594 countsByYear W20725375942012 @default.
- W2072537594 countsByYear W20725375942014 @default.
- W2072537594 countsByYear W20725375942015 @default.
- W2072537594 countsByYear W20725375942016 @default.
- W2072537594 countsByYear W20725375942017 @default.
- W2072537594 countsByYear W20725375942018 @default.
- W2072537594 countsByYear W20725375942020 @default.
- W2072537594 countsByYear W20725375942021 @default.
- W2072537594 countsByYear W20725375942022 @default.
- W2072537594 countsByYear W20725375942023 @default.
- W2072537594 crossrefType "journal-article" @default.
- W2072537594 hasAuthorship W2072537594A5014897645 @default.
- W2072537594 hasAuthorship W2072537594A5022692101 @default.
- W2072537594 hasAuthorship W2072537594A5022734219 @default.
- W2072537594 hasAuthorship W2072537594A5033522929 @default.
- W2072537594 hasAuthorship W2072537594A5069526986 @default.
- W2072537594 hasAuthorship W2072537594A5089683087 @default.
- W2072537594 hasConcept C126322002 @default.
- W2072537594 hasConcept C126894567 @default.
- W2072537594 hasConcept C134018914 @default.
- W2072537594 hasConcept C170493617 @default.
- W2072537594 hasConcept C197934379 @default.
- W2072537594 hasConcept C2777428134 @default.
- W2072537594 hasConcept C2778058571 @default.
- W2072537594 hasConcept C2778258207 @default.
- W2072537594 hasConcept C2778715236 @default.
- W2072537594 hasConcept C2778938600 @default.
- W2072537594 hasConcept C2779064019 @default.
- W2072537594 hasConcept C2779234561 @default.
- W2072537594 hasConcept C2779832395 @default.
- W2072537594 hasConcept C54355233 @default.
- W2072537594 hasConcept C71315377 @default.
- W2072537594 hasConcept C71924100 @default.
- W2072537594 hasConcept C86803240 @default.
- W2072537594 hasConcept C90924648 @default.
- W2072537594 hasConceptScore W2072537594C126322002 @default.
- W2072537594 hasConceptScore W2072537594C126894567 @default.
- W2072537594 hasConceptScore W2072537594C134018914 @default.
- W2072537594 hasConceptScore W2072537594C170493617 @default.
- W2072537594 hasConceptScore W2072537594C197934379 @default.
- W2072537594 hasConceptScore W2072537594C2777428134 @default.
- W2072537594 hasConceptScore W2072537594C2778058571 @default.
- W2072537594 hasConceptScore W2072537594C2778258207 @default.
- W2072537594 hasConceptScore W2072537594C2778715236 @default.
- W2072537594 hasConceptScore W2072537594C2778938600 @default.
- W2072537594 hasConceptScore W2072537594C2779064019 @default.
- W2072537594 hasConceptScore W2072537594C2779234561 @default.
- W2072537594 hasConceptScore W2072537594C2779832395 @default.
- W2072537594 hasConceptScore W2072537594C54355233 @default.
- W2072537594 hasConceptScore W2072537594C71315377 @default.
- W2072537594 hasConceptScore W2072537594C71924100 @default.
- W2072537594 hasConceptScore W2072537594C86803240 @default.
- W2072537594 hasConceptScore W2072537594C90924648 @default.
- W2072537594 hasIssue "6" @default.
- W2072537594 hasLocation W20725375941 @default.
- W2072537594 hasLocation W20725375942 @default.
- W2072537594 hasOpenAccess W2072537594 @default.
- W2072537594 hasPrimaryLocation W20725375941 @default.
- W2072537594 hasRelatedWork W1966625438 @default.
- W2072537594 hasRelatedWork W1970823640 @default.
- W2072537594 hasRelatedWork W1990399071 @default.
- W2072537594 hasRelatedWork W2035021492 @default.
- W2072537594 hasRelatedWork W2060076556 @default.
- W2072537594 hasRelatedWork W2079101059 @default.
- W2072537594 hasRelatedWork W2093676636 @default.
- W2072537594 hasRelatedWork W2120307014 @default.
- W2072537594 hasRelatedWork W2121446313 @default.
- W2072537594 hasRelatedWork W2127836255 @default.
- W2072537594 hasVolume "126" @default.
- W2072537594 isParatext "false" @default.
- W2072537594 isRetracted "false" @default.
- W2072537594 magId "2072537594" @default.
- W2072537594 workType "article" @default.